Clinical Trial Update: Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms [Phase 2, Phase 3]

View source ↗

Summary

A pharmacogenomics study evaluating how single nucleotide polymorphisms may influence Alectinib treatment in non-small cell lung cancer, conducted in Phase 2 an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alectinib (alectinib)

Snippet

Sponsor: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | Conditions: Non-small Cell Lung Cancer | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING